Lisata Therapeutics, Inc. (LSTA) News
Follow Lisata Therapeutics, Inc. (LSTA) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 5 public stories across 5 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
H
Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces Upcoming Late-Breaking Presentation of MAR001 Clinical Data at the American Heart Association Scientific Sessions 2026
Late-breaking presentation will highlight Phase 2b clinical data for MAR001, a potential first-in-class antibody targeting ANGPTL4 designed to lower triglycerides and improve metabolic functionSOUTH SAN FRANCISCO and LIB
NEWS | Sep 24, 2026, 12:03 PM UTC
L
LSTA - Lisata Therapeutics Announces Acquisition of Marea Therapeutics and $225 Million Concurrent Private Placement
LSTA - Lisata Therapeutics Announces Acquisition of Marea Therapeutics and $225 Million Concurrent Private Placement
MNA | Sep 17, 2026, 01:34 PM UTC
H
LSTA - Lisata Therapeutics Provides Update Following Termination of Merger Agreement
LSTA - Lisata Therapeutics Provides Update Following Termination of Merger Agreement
MNA | Aug 04, 2026, 11:00 AM UTC
H
Lisata Therapeutics terminates merger with Kuva Labs
In a regulatory filing on...
EQUITY | Jul 27, 2026, 02:07 PM UTC
H
LSTA Lisata Therapeutics - terminates merger agreement with kuva Labs on July 24, 2026 - SEC filing - Termination due to kuva Labs' failure
LSTA Lisata Therapeutics - terminates merger agreement with kuva Labs on July 24, 2026 - SEC filing - Termination due to kuva Labs' failure to obtain financing and accept tendered shares - SEC filing - Board to assess st
MNA | Jul 24, 2026, 04:18 PM UTC